CANF vs RCUS vs IMVT vs CRL vs IQV

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Can-Fite BioPharma Ltd. (CANF) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, IQVIA Holdings Inc.

is actually cheaper at 14. 1x.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -82. 6% for Can-Fite BioPharma Ltd. (CANF). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus CANF's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd.

(CANF) is the lower-risk stock at 0. 88β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 122% more volatile than CANF relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). On earnings-per-share growth, the picture is similar: Can-Fite BioPharma Ltd. grew EPS 40. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -1169. 1% for Can-Fite BioPharma Ltd. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -1206. 2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 1x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANF: 104. 8% to $7. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Can-Fite BioPharma Ltd.

(CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CANF: -99. 1%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.